Regarding endogenous IL-10, the administration of antibodies against IL-10 increased IL-1β in steatotic liver grafts from DBDs, in comparison with LT from DBDs without treatment (that is, BD+anti-IL-10+LT vs. BD+LT), whereas the levels of IL-1β in liver grafts where there was an absence of steatosis were found to be similar in the BD+anti-IL-10+LT group and in the BD+LT group (Figure 1B). This evidence concerns the gene IL10 and Behcet disease.